Jul 18, 2021
FRIDAY, July 16, 2021 (HealthDay News) Pfizer Inc. has agreed to pay $345 million in a proposed settlement to resolve lawsuits over steep EpiPen price increases.
In 2016, a number of class-action lawsuits were filed against Pfizer and its subsidiaries Meridian Medical Technologies Inc. and King Pharmaceuticals, alleging they engaged in anticompetitive conduct related to EpiPen, the
Associated Press reported.
Court documents filed Thursday in federal court in Kansas City, Kansas, show that Pfizer and its two subsidiaries asked the court to give preliminary approval to the settlement, according to Kansas City’s NPR station KCUR-FM, the
AP reported. In an email to KCUR-FM, a Pfizer spokesperson denied any wrongdoing by the company and said the settlement was sought to avoid “the distraction of continued litigation and focus on breakthroughs that change patients’ lives.”
Stocks close lower, EpiPen price hike settlement agreement
NEW YORK (AP) Stocks closed lower on Wall Street today, pulling major indexes a bit further below the record highs they marked at the start of the week. Investors continue to focus on where the economy is headed as the pandemic wanes, and also on the latest company earnings reports. The S&P index fell 0.3%. Technology and communications stocks were the biggest weights on the market. Banks, which have been reporting mostly solid financial results, also fell as bond yields headed lower. Jobless claims fell to another pandemic low.
KANSAS CITY, Kansas (AP) Pfizer Inc. and two of its subsidiaries have agreed to pay $345 million under a proposed settlement to resolve litigation over EpiPen price hikes. Pfizer and its subsidiaries Meridian Medical Technologies Inc. and King Pharmaceuticals, asked a federal court to grant preliminary approval to the settlement today. Numerous class action lawsuits were filed alleging the comp
Pfizer and two of its subsidiaries agree to pay $345 million settlement over EpiPen price hikes Updated: 5:20 PM EDT Jul 15, 2021 Associated Press Share Updated: 5:20 PM EDT Jul 15, 2021
Hide Transcript
Show Transcript REPORTER: SEVEN-YEAR-OLD AIDEN SEGOOL LOOKS JUST LIKE ANY OTHER KID ABOUT TO START SCHOOL. BUT WHAT YOU CAN’T SEE IS THAT AIDEN HAS A LIFE-THREATENING ALLERGY TO DAIRY AND EGGS. EVERYONE GETS TO EAT AROUND ME, BUT I CAN’T. REPORTER: IT IS SOMETHING HIS PARENTS DISCOVERED THE FIRST TIME HE TRIED YOGURT AS A BABY. ALL OF A SUDDEN, SOMETHING DIDN’T SEEM RIGHT. I GOT NERVOUS, I TOOK HIS SHIRT OFF AND HE WAS COVERED IN HIVES. REPORTER: MOM ALYSON WAS PRESCRIBED AN EPINEPHRINE AUTO-INJECTOR, THEN TRAINED HOW TO USE IT. AND SHE LEARNED TO ASK THE PHARMACY ABOUT ITS EXPIRATION DATE. THEY’RE GRABBING ONE OFF THE SHELF THAT’S EXPIRING IN 4 MONTHS. NOT ONLY DO YOU HAVE TO GO BACK IN 4 MONTHS BUT YOU’VE SPENT THE MONEY
Pfizer, Subsidiaries Agree to Pay $345M in EpiPen Settlement EpiPens, auto-injectable devices that deliver the drug epinephrine, are used for emergency treatment of a life-threatening allergic reaction
Published July 15, 2021
AP
Pfizer Inc. and two of its subsidiaries have agreed to pay $345 million under a proposed settlement to resolve lawsuits over EpiPen price hikes.
In documents filed Thursday in federal court in Kansas City, Kansas, the New York-based Pfizer and its subsidiaries Maryland-based Meridian Medical Technologies Inc. and Tennessee-based King Pharmaceuticals asked the court to grant preliminary approval to the settlement, Kansas City s NPR station KCUR-FM reported. Don t miss local breaking news and weather. Download
News in brief arkansasonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from arkansasonline.com Daily Mail and Mail on Sunday newspapers.